Kathleen Burlison, MD
Internal Medicine · Fairfield, CTNPI 1205862679
Payments from drug & device makers
Across 133 payments — averaging $22.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$457
- AbbVie$395
- Novo Nordisk$317
- Lilly USA, LLC$241
- Pfizer$226
- Astellas Pharma US Inc$183
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,65890%
- Education$31110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $457 |
| AbbVie | 18 | $395 |
| Novo Nordisk | 17 | $317 |
| Lilly USA, LLC | 10 | $241 |
| Pfizer | 10 | $226 |
| Astellas Pharma US Inc | 6 | $183 |
| Boehringer Ingelheim | 9 | $164 |
| GSK | 6 | $142 |
| Exact Sciences | 5 | $135 |
| Amgen | 5 | $117 |
| Otsuka America Pharmaceutical, Inc. | 4 | $92 |
| Bayer | 2 | $65 |
| E.r. Squibb & Sons, L.L.C. | 3 | $58 |
| Sanofi-aventis U.S. LLC | 2 | $54 |
| Abbott | 2 | $49 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| Seqirus USA Inc | 1 | $33 |
| Inspire Medical Systems, Inc. | 1 | $33 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
| Merck | 1 | $22 |
| Mylan Specialty L.p. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Viatris Specialty LLC | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Shield Therapeutics Inc | 1 | $15 |
How this compares
$2,969 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 124 | $131,201 |
| JardianceEmpagliflozin | 78 | $91,584 |
| EliquisApixaban | 65 | $61,095 |
| JanuviaSitagliptin Phosphate | 39 | $60,460 |
| MounjaroTirzepatide | 30 | $39,603 |
| TrulicityDulaglutide | 30 | $37,084 |
| ProliaDenosumab | 21 | $36,719 |
| RybelsusSemaglutide | 30 | $30,045 |
| LinzessLinaclotide | 29 | $28,777 |
| FarxigaDapagliflozin Propanediol | 30 | $27,034 |
| MyrbetriqMirabegron | 30 | $24,888 |
| XareltoRivaroxaban | 22 | $21,948 |
| TradjentaLinagliptin | 25 | $17,379 |
| RexultiBrexpiprazole | 11 | $17,373 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $13,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $317 | $161,246154 claims |
| Boehringer IngelheimJardiance, Tradjenta | $164 | $108,963103 claims |
| Lilly USA, LLCMounjaro, Trulicity | $241 | $76,68760 claims |
| PfizerEliquis | $226 | $61,09565 claims |
| MerckJanuvia | $22 | $60,46039 claims |
| AbbVieLinzess, Synthroid | $395 | $36,902120 claims |
| AmgenProlia | $117 | $36,71921 claims |
| AstraZenecaFarxiga, Symbicort | $457 | $30,79649 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $142 | $26,73450 claims |
| Astellas Pharma US IncMyrbetriq | $183 | $24,88830 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $92 | $17,37311 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $22 | $4,922503 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Fairfield
- Naeem SarfrazFairfield$31K
- Joseph SouferWaterbury$21.5M
- David RadinStamford$7M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Charles MontanoCromwell$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
- Gary BlickNorwalk$717K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.